الانتقال إلى المحتوى الرئيسي
xMedica

NCT07919678ClinicalTrials.gov

A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY BEROBENATIDE IN ADULTS WITH KNEE OSTEOARTHRITIS AND OVERWEIGHT OR OBESITY (VESPER-OA 1)

قيد التجنيديقبل مشاركين الآن، وفقاً لسجل السجل.
التواصل مع هذه الدراسة

باختصار

The purpose of this clinical study is to learn about the safety and effects of berobenatide (PF-08653944) for the treatment of knee osteoarthritis in adults with overweight or obesity. The study will last 52 weeks and compare the effects of…

المرحلة 3مطلوب 656 مشاركاً40 موقعاًدولتان

الفئات

مسجَّلة في سجل واحد

يمكن أن تُسجَّل دراسة واحدة في عدة سجلات. نعرضها مرة واحدة ونربط بكل سجل نحتفظ به.

تُعرض معلومات التجربة كما نشرها السجل، بلغتها الأصلية.

هل أنت مهتم بهذه الدراسة؟

تسجيل الدخول أو أنشئ حسابًا لتسجيل اهتمامك ومتابعة هذه الدراسة.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 10 days after the recorded start)First posted 2026-11-05; recorded start 2026-10-26
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 635 other studies in this databaseCounted from the lead sponsor named in the record (Pfizer)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 3 conditions.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourDEFINITIVE

A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 40 sites

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study, international in scope: 656 participants (target), run at 40 sites, across 2 countries.

How this score is built
  • Enrolment28/40

    656 participants (target)

  • Site count19/25

    40 sites

  • Country count7/15

    2 countries

  • Planned duration7/10

    Planned over about 24 months

  • Sponsor scale10/10

    Pfizer has led 630 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

ملخص

The purpose of this clinical study is to learn about the safety and effects of berobenatide (PF-08653944) for the treatment of knee osteoarthritis in adults with overweight or obesity. The study will last 52 weeks and compare the effects of berobenatide compared to placebo on knee pain, physical function, and body weight. Study activities will include blood tests, knee pain assessment, physical function questionnaires and body measurements.

الحالات

  • Obesity
  • Overweight
  • Osteoarthritis of the Knee

الأهلية

الأهلية
الجنسالجميع
الأعمار18 Years – لا حد أقصى
المتطوعون الأصحّاءلا

الأهلية كما كُتبت في السجل

Inclusion Criteria: * Adults 18 years of age or older, or the minimum age of consent according to local regulations. * Body mass index of at least 27 kg/m² at Screening. * Currently meets American College of Rheumatology (ACR) Criteria for knee OA. * Pain due to knee OA. * Knee radiograph consistent with knee osteoarthritis and Kellgren-Lawrence Grade 2 or 3. * Willingness to complete the required analgesic washout. * History of at least 1 self-reported unsuccessful dietary effort to lose body weight. Exclusion Criteria * Self-reported body weight increase or decrease greater than 5% within 90 days before Screening. * History of diabetes or Screening laboratory findings indicative of diabetes. * Known clinically significant gastric-emptying abnormality, history of acute or chronic pancreatitis, or active symptomatic gallbladder disease. * Personal history or first-degree family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. * Significant active or unstable psychiatric disorder. * Condition or knee disorder that could confound assessment of target-knee pain. * Prior target-knee replacement, planned target-knee replacement, or planned elective knee surgery during the study. * Recent use of weight-loss medication, any glucose-lowering therapy, or other protocol-prohibited treatment. * Prior participation in a berobenatide clinical trial with receipt of active treatment or placebo. * Hypersensitivity to a drug with glucagon-like peptide-1 receptor activity, including berobenatide, or any excipient.

الأهلية في عبارات بسيطة

لم تُقسَّم معايير هذا السجل إلى عبارات منفصلة بعد. نص السجل أعلاه كامل وهو النسخة المُعتمَدة.

تصميم الدراسة

تصميم الدراسة
نوع الدراسةتدخّلية
المرحلةالمرحلة 3
التخصيصمعشّاة
نموذج التدخّلPARALLEL
الغرض الأساسيTREATMENT
التعميةQUADRUPLE (4)
التجنيدمطلوب 656 مشاركاً

الجهة الراعية والمتعاونون

  • Pfizer الجهة الراعية

الأذرع والتدخلات

  • PlaceboPLACEBO_COMPARATOR

    Participants will receive placebo as subcutaneous injection

  • Arm 1: Berobenatide Once MonthlyEXPERIMENTAL

    Participants will receive berobenatide by subcutaneous injection.

  • Arm 2: Berobenatide Once MonthlyEXPERIMENTAL

    Participants receive berobenatide by subcutaneous injection.

  • Arm 3: Berobenatide Once MonthlyEXPERIMENTAL

    Participants receive berobenatide by subcutaneous injection.

التدخلات

  • دواء Berobenatide

    Subcutaneous Injection

  • أخرى Placebo

    Subcutaneous Injection

مقاييس النتائج

  1. مقياس النتيجة الأولي

    Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale score

    الإطار الزمني Baseline and Week 52

  2. مقياس النتيجة الثانوي

    Percent change from baseline in Body Weight

    الإطار الزمني Baseline and Week 52

  3. مقياس النتيجة الثانوي

    Change From Baseline in High-Sensitivity C-Reactive Protein

    الإطار الزمني Baseline and Week 52

  4. مقياس النتيجة الثانوي

    Change from baseline in WOMAC Physical Function Subscale score

    الإطار الزمني Baseline and Week 52

  5. مقياس النتيجة الثانوي

    Percentage of participants with ≥50% reduction in the WOMAC pain subscale score

    الإطار الزمني Baseline and Week 52

  6. مقياس النتيجة الثانوي

    Percentage of participants with ≥30% reduction in the WOMAC pain subscale score

    الإطار الزمني Baseline and Week 52

  7. مقياس النتيجة الثانوي

    Proportion of participants with utilization of protocol specified pain medication during the washout period

    الإطار الزمني Baseline and Week 52

  8. مقياس النتيجة الثانوي

    Amount of protocol specified pain medication during the washout period

    الإطار الزمني Baseline and Week 52

  9. مقياس النتيجة الثانوي

    Change from baseline in WOMAC stiffness score

    الإطار الزمني Baseline and Week 52

  10. مقياس النتيجة الثانوي

    Change from baseline in WOMAC total score

    الإطار الزمني Baseline and Week 52

  11. مقياس النتيجة الثانوي

    Proportion of participants achieving ≥50% reduction in the WOMAC physical function subscale score

    الإطار الزمني Baseline and Week 52

  12. مقياس النتيجة الثانوي

    Proportion of participants meeting OMERACT-OARSI

    الإطار الزمني Baseline and Week 52

  13. مقياس النتيجة الثانوي

    Change from baseline in Average Pain Intensity-Numerical Rating Score

    الإطار الزمني Baseline and Week 52

  14. مقياس النتيجة الثانوي

    Change from baseline in Worst Pain Intensity -Numerical Rating Score

    الإطار الزمني Baseline and Week 52

  15. مقياس النتيجة الثانوي

    Change from baseline in SF-36 domain scales and component summary scales

    الإطار الزمني Baseline and Week 52

  16. مقياس النتيجة الثانوي

    Change from baseline in Body Weight

    الإطار الزمني Baseline and Week 52

  17. مقياس النتيجة الثانوي

    Change from Baseline in Body Mass Index

    الإطار الزمني Baseline and Week 52

  18. مقياس النتيجة الثانوي

    Number of participants with Treatment Emergent Adverse Events (TEAEs)

    الإطار الزمني Baseline and Week 52

  19. مقياس النتيجة الثانوي

    Number of Participants with Serious Adverse Events (SAE)

    الإطار الزمني Baseline and Week 52

  20. مقياس النتيجة الثانوي

    Number of Participants with AE leading to permanent discontinuation from study intervention or study

    الإطار الزمني Baseline and Week 52

  21. مقياس النتيجة الثانوي

    Number of Participants with Adverse Events of Special Interest (AESI)

    الإطار الزمني Baseline and Week 52

  22. مقياس النتيجة الثانوي

    Number of Participants with Clinical laboratory abnormalities

    الإطار الزمني Baseline and Week 52

  23. مقياس النتيجة الثانوي

    Change from baseline in timed walking distance at Week 52

    الإطار الزمني Baseline and Week 52

  24. مقياس النتيجة الثانوي

    Percentage of Participants Reporting Improvement in Patient Global Impression of Severity (PGI-S) for knee-OA related physical function

    الإطار الزمني Baseline and Week 52

  25. مقياس النتيجة الثانوي

    Percentage of Participants Reporting Improvement in Patient Global Impression of Severity (PGI-S) for knee-OA pain

    الإطار الزمني Baseline and Week 52

  26. مقياس النتيجة الثانوي

    Percentage of Participants Reporting Improvement in Patient Global Impression of Change (PGI-C) for knee-OA related physical function

    الإطار الزمني Baseline and Week 52

  27. مقياس النتيجة الثانوي

    Percentage of Participants Reporting Improvement in Patient Global Impression of Change PGI-C for knee-OA pain

    الإطار الزمني Baseline and Week 52

  28. مقياس النتيجة الثانوي

    Change From Baseline in EuroQol 5-Dimension, 5-Level (EQ-5D-5L) Index Score

    الإطار الزمني Baseline and Week 52

  29. مقياس النتيجة الثانوي

    Change From Baseline in EuroQol-visual analog scale (EQ-VAS) Score

    الإطار الزمني Baseline and Week 52

  30. مقياس النتيجة الثانوي

    Change From Baseline in Work Productivity and Activity Impairment - General Health (WPAI:GH) Absenteeism Score

    الإطار الزمني Baseline and Week 52

  31. مقياس النتيجة الثانوي

    Change From Baseline in WPAI:GH Work productivity loss score

    الإطار الزمني Baseline and Week 52

  32. مقياس النتيجة الثانوي

    Change From Baseline in WPAI:GH Activity impairment score

    الإطار الزمني Baseline and Week 52

  33. مقياس النتيجة الثانوي

    Change From Baseline in Systolic Blood Pressure (SBP)

    الإطار الزمني Baseline and Week 52

  34. مقياس النتيجة الثانوي

    Change From Baseline in Diastolic Blood Pressure (DBP)

    الإطار الزمني Baseline and Week 52

  35. مقياس النتيجة الثانوي

    Change From Baseline in Total Cholesterol

    الإطار الزمني Baseline and Week 52

  36. مقياس النتيجة الثانوي

    Change From Baseline in High-density lipoprotein cholesterol (HDL-C)

    الإطار الزمني Baseline and Week 52

  37. مقياس النتيجة الثانوي

    Change From Baseline in Low-density lipoprotein cholesterol (LDL-C)

    الإطار الزمني Baseline and Week 52

  38. مقياس النتيجة الثانوي

    Change from baseline in Non-HDL Cholesterol

    الإطار الزمني Baseline and Week 52

  39. مقياس النتيجة الثانوي

    Change from baseline in Very low-density lipoprotein cholesterol (VLDL) Cholesterol

    الإطار الزمني Baseline and Week 52

  40. مقياس النتيجة الثانوي

    Change from baseline in Triglycerides

    الإطار الزمني Baseline and Week 52

التواريخ

التواريخ
تاريخ البدء26 أكتوبر 2026 (فعلي)
الإتمام الأولي22 أغسطس 2028 (تقديري)
الإتمام10 أكتوبر 2028 (تقديري)
أول نشر5 نوفمبر 2026 (فعلي)
آخر تحديث5 نوفمبر 2026
النتائج منشورةغير مذكور في سجل السجل
آخر تأكيد للحالةأكتوبر 2026

فعلي يعني أن الحدث وقع. تقديري يعني أن الجهة الراعية تتوقعه. للكلمتين معنيان مختلفان.

المواقع

7 مواقع قيد التجنيد

Canada

Canada
المنشأةالمدينةالولاية أو المنطقةالحالة
Bluewater Clinical Research Group Inc.SarniaOntarioلم يبدأ التجنيد بعد

United States

United States
المنشأةالمدينةالولاية أو المنطقةالحالة
Albuquerque Clinical Trials, Inc.AlbuquerqueNew Mexicoلم يبدأ التجنيد بعد
Charlottesville Medical Research Center, LLCCharlottesvilleVirginiaلم يبدأ التجنيد بعد
Northwestern University Feinberg School Of MedicineChicagoIllinoisلم يبدأ التجنيد بعد
Great Lakes Clinical Trials, LLC dba Flourish ResearchChicagoIllinoisلم يبدأ التجنيد بعد
Northwestern MedicineChicagoIllinoisلم يبدأ التجنيد بعد
Northwestern Memorial Hospital, Diagnostic Testing Center (Phlebotomy/EKG)ChicagoIllinoisلم يبدأ التجنيد بعد
Northwestern Memorial Hospital, Investigational Drug ServiceChicagoIllinoisلم يبدأ التجنيد بعد
Clinical Research of West Florida, Inc.ClearwaterFloridaلم يبدأ التجنيد بعد
Skylight Health ResearchColorado SpringsColoradoلم يبدأ التجنيد بعد
Mercy Family ClinicDallasTexasلم يبدأ التجنيد بعد
Universal Axon Clinical Research LLCDoralFloridaقيد التجنيد
Altoona Center For Clinical ResearchDuncansvillePennsylvaniaقيد التجنيد
Headlands Research California, LLCEscondidoCaliforniaلم يبدأ التجنيد بعد
Profound Research LLCFarmington HillsMichiganقيد التجنيد
Cedar Health ResearchFort WorthTexasلم يبدأ التجنيد بعد
Novant Health Granite Quarry Internal Medicine (knee x-ray)Granite QuarryNorth Carolinaلم يبدأ التجنيد بعد
BRCR Global LouisianaGretnaLouisianaلم يبدأ التجنيد بعد
JCCT-JUNO NW HoustonHoustonTexasلم يبدأ التجنيد بعد
Westside Center for Clinical ResearchJacksonvilleFloridaلم يبدأ التجنيد بعد
Activian Clinical ResearchKingwoodTexasلم يبدأ التجنيد بعد
Renstar Medical ResearchLady LakeFloridaلم يبدأ التجنيد بعد
Monroe Biomedical ResearchMonroeNorth Carolinaقيد التجنيد
AMR ClinicalNormanOklahomaلم يبدأ التجنيد بعد
Renstar Medical ResearchOcalaFloridaلم يبدأ التجنيد بعد
Prospective Research Innovations Inc.Rancho CucamongaCaliforniaلم يبدأ التجنيد بعد
Accellacare - SalisburySalisburyNorth Carolinaلم يبدأ التجنيد بعد
Consano Clinical Research, LLCShavano ParkTexasلم يبدأ التجنيد بعد
Revive Research Institute, Inc.Sterling HeightsMichiganقيد التجنيد
Clinical Research AtlantaStockbridgeGeorgiaلم يبدأ التجنيد بعد
Clinical Research of West Florida, Inc.TampaFloridaلم يبدأ التجنيد بعد
AMR ClinicalTempeArizonaلم يبدأ التجنيد بعد
DM Clinical ResearchTomballTexasلم يبدأ التجنيد بعد
Solace Clinical ResearchTustinCaliforniaلم يبدأ التجنيد بعد
Velocity Clinical Research, WacoWacoTexasلم يبدأ التجنيد بعد
Elevate Clinical ResearchWichitaKansasلم يبدأ التجنيد بعد
Delaney RadiologistWilmingtonNorth Carolinaقيد التجنيد
AccellacareWilmingtonNorth Carolinaقيد التجنيد
North Georgia Internal MedicineWoodstockGeorgiaلم يبدأ التجنيد بعد
North Georgia Clinical Research, LLCWoodstockGeorgiaلم يبدأ التجنيد بعد

مستندات الدراسة

لا تُرتبط أي مستندات في سجل السجل هذا.

التغيّرات عبر الزمن

لم تُسجَّل أي تغييرات منذ أن أدرجنا هذا السجل لأول مرة.

يُسجَّل تغيير في كل مرة تحدّث فيها الجهة الراعية سجل السجل. تظهر هنا الحالة والتواريخ والتجنيد والمواقع كلما تغيّرت.